All Stories

Gilead loses interest in Arcus' kidney cancer rival to Merck's Welireg

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.

Feb 18, 2025 - 14:57
 0
Gilead loses interest in Arcus' kidney cancer rival to Merck's Welireg
Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.
Read More

Tags:

Previous Article

Nike teams up with Skims to launch new women’s activewear brand

Next Article

European medicines agencies network strategy (EMANS) to 2028 webinar, Online, Eu...

Related Posts

Aardvark heads to Nasdaq with $94M IPO to fund more appetite-suppressant trials

Aardvark heads to Nasdaq with $94M IPO to fund more app...

Feb 13, 2025  0

Siemens Healthineers plans 'mega depots' to bolster US supply chain amid 'geopolitical uncertainties'

Siemens Healthineers plans 'mega depots' to bolster US ...

Feb 19, 2025  0

DNA sequencing shares slide amid 'headwinds' from Trump's NIH funding cuts

DNA sequencing shares slide amid 'headwinds' from Trump...

Feb 10, 2025  0